{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:11:15Z","timestamp":1761109875423},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1157\/13116748","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T22:30:06Z","timestamp":1208903406000},"page":"127-134","source":"Crossref","is-referenced-by-count":21,"title":["Estudio longitudinal de adherencia, satisfacci\u00f3n y efectividad del tratamiento antirretroviral administrado una vez al d\u00eda, frente a dos veces al d\u00eda, en una cohorte espa\u00f1ola de infectados por el VIH (estudio CUVA: cualquiera una vez al d\u00eda)"],"prefix":"10.1016","volume":"26","author":[{"given":"Pompeyo","family":"Viciana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteve","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R.","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"P\u00e9rez-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13116748_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-131-2-199907200-00002","article-title":"Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions","volume":"131","author":"Lucas","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1157\/13116748_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1157\/13116748_bb0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13116748_bb0025","series-title":"7th European Conference on Clinical Aspects and treatment of HIV-Infection","article-title":"Adherence to antiretroviral therapy: The patient's perspective","author":"Knobel","year":"1999"},{"key":"10.1157\/13116748_bb0030","series-title":"6th International Congress on Drug Therapy in HIV-Infection","article-title":"The APPT-1 Study: Assessing Patients\u2019 Preferred Treatments","author":"Moyle","year":"2002"},{"key":"10.1157\/13116748_bb0035","series-title":"14th World AIDS Conference","article-title":"HIV patients prefers once-daily regimens","author":"Bass","year":"2002"},{"key":"10.1157\/13116748_bb0040","series-title":"4th International Congress on Drug Therapy in HIV Infection","article-title":"Perceived influence of regimen characteristics on adherence","author":"Jordan","year":"2000"},{"key":"10.1157\/13116748_bb0045","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1086\/374602","article-title":"Once-a-day highly active antiretroviral therapy: A systematic review","volume":"36","author":"Ena","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13116748_bb0050","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2165\/00003088-200342140-00001","article-title":"Once-daily administration of antiretrovirals. Pharmacokinetics of emerging therapies","volume":"42","author":"Taburet","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1157\/13116748_bb0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1468-1293.2000.00020.x","article-title":"A simple, once-daily doping regimen for treating HIV-1 infection in intravenous drug users","volume":"1","author":"Staszewski","year":"2000","journal-title":"HIV Medicine"},{"key":"10.1157\/13116748_bb0060","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/00002030-200305020-00010","article-title":"Once-a-day highly active antiretroviral therapy in treatment-na\u00efve HIV-1-infected adults in Senegal","volume":"17","author":"Landman","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13116748_bb0065","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0140-6736(01)05550-7","article-title":"Community-based approaches to HIV treatment in resource-poor setting","volume":"358","author":"Farmer","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13116748_bb0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/135965350200600404","article-title":"Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz","volume":"6","author":"Maggiolo","year":"2001","journal-title":"Antivir Ther"},{"key":"10.1157\/13116748_bb0075","series-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","article-title":"Panel on Clinical Practices for Treatment of HIV convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation","year":"2004"},{"key":"10.1157\/13116748_bb0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1157\/13096750","article-title":"Plan Nacional Sobre el SIDA. Recomendaciones de GESIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (Enero 2007)","volume":"25","author":"Panel de expertos de Gesida","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13116748_bb0085","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compilance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1157\/13116748_bb0090","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0149-2918(02)85026-3","article-title":"Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis","volume":"24","author":"Iskedjian","year":"2002","journal-title":"Clin Ther"},{"key":"10.1157\/13116748_bb0095","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-200107270-00006","article-title":"Overview of the effectiveness of triple combination therapy in antiretroviral-na\u00efve HIV-1 infected adults","volume":"15","author":"Bartlett","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13116748_bb0100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0213-005X(04)73044-X","article-title":"Estrategias para optimizar la adherencia al tratamiento antirretroviral. Intervenciones en la pauta terap\u00e9utica","volume":"22","author":"Knobel","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13116748_bb0105","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/00002030-200205240-00021","article-title":"Intracellular carbovir triphosphate levels in patients taking abacavir once a day","volume":"16","author":"Harris","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13116748_bb0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00002030-200005260-00001","article-title":"The steady-state pharmacokinetics of nevirapine during oncedaily and twice daily doping in HIV-infected individuals","volume":"14","author":"Van Heeswijk","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13116748_bb0115","series-title":"43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Saquinavir\/ ritonavir pharmacokinetics in HIV-positive subjects: 1,000\/100 mg BD vs 1,600\/100 and 2,000\/100 mg once-daily (OD)","author":"Boffito","year":"2003"},{"issue":"35","key":"10.1157\/13116748_bb0120","first-page":"22","article-title":"SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir\/ ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients","volume":"18","author":"Gathe","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13116748_bb0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/315711","article-title":"Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients","volume":"182","author":"Molina","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1157\/13116748_bb0130","series-title":"Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection","article-title":"Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in treatment na\u00efve HIV-infected adults: 96-week follow-up of the ANRS 091 trial","author":"Molina","year":"2001"},{"key":"10.1157\/13116748_bb0135","series-title":"7th International Congress on Drug Therapy in HIV infection","article-title":"The combination of tenofovir DF, emtricitabine and efavirenz has significantly greater response vs fixed dose zidovudine\/lamivudine and efavirenz in antiretroviral naive patients: A 24-week preliminary analysis","author":"Arribas","year":"2004"},{"key":"10.1157\/13116748_bb0140","series-title":"Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"A controlled, randomized, prospective study on a once-a-day therapy for HIV infection","author":"Maggiolo","year":"2002"},{"key":"10.1157\/13116748_bb0145","series-title":"43rd Interscience Conference on Antiretroviral Agents and Chemotherapy","article-title":"Abacavir once-daily (OAD) plus lamivudine (OAD) in combination with efavirenz (OAD) is well-tolerated and effective in the treatment of antiretroviral therapy naive adults with HIV-1 Infection (ZODIAC Study: CNA30021)","author":"Gazzard","year":"2003"},{"key":"10.1157\/13116748_bb0150","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1086\/428091","article-title":"Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial","volume":"191","author":"Molina","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1157\/13116748_bb0155","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00042560-200107010-00007","article-title":"A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection","volume":"27","author":"Mole","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13116748_bb0160","series-title":"11th Conference on Retroviruses and Opportunistic Infections","article-title":"Once-daily vs twice-daily lopinavir\/ritonavir in antiretroviral-naive patients: 48-week results","author":"Gathe","year":"2004"},{"key":"10.1157\/13116748_bb0165","series-title":"Sixth International Congress on Drug Therapy in HIV Infection","article-title":"pharmacokinetics Evaluation of Tenofovir DF and Enteric-Coated Didanosine","author":"Kearney","year":"2002"},{"key":"10.1157\/13116748_bb0170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antirretroviral-naive patients. A 3 year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13116748_bb0175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.292.2.180","article-title":"for the EMTRICITABINA-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antirretroviral-na\u00efve patients","volume":"292","author":"Saag","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13116748_bb0180","series-title":"8th European Conference on Clinic Aspects and Treatment of HIV-Infection","article-title":"Better virologic suppression after substitution of protease inhibitors with efavirenz in patients with undetectable viral loads","author":"Katlama","year":"2001"},{"key":"10.1157\/13116748_bb0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1468-1293.2003.00139.x","article-title":"TRIZAL study: Switching from successful HAART to trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results","volume":"4","author":"Katlama","year":"2003","journal-title":"HIV Med"},{"key":"10.1157\/13116748_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0025-7753(03)73925-6","article-title":"Tratamiento antirretroviral de gran actividad administrado una vez al d\u00eda: \u00bfpresente o futuro?","volume":"121","author":"Pulido","year":"2002","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13116748_bb0195","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1128\/AAC.43.11.2629","article-title":"Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture","volume":"43","author":"Nascimbeni","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13116748_bb0200","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1086\/386344","article-title":"A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection","volume":"189","author":"Dybul","year":"2004","journal-title":"J Infect Dis"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08726752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08726752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T22:07:33Z","timestamp":1684361253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X08726752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0213005X08726752"],"URL":"https:\/\/doi.org\/10.1157\/13116748","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}